Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 4, 2014, Pages 698-708

  Chang, Yu Chao ^a,b   Tsai, Chung Hung ^a,b   Lai, You Liang ^a   Yu, Cheng Chia ^a,b   Chi, Wan Yu ^a   Li, Jung Jung ^a   Chang, Wen Wei ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arecoline; Buccal mucosal fibroblasts; Myofibroblasts; Oral submucous fibrosis; ZEB1; SMA

Indexed keywords

ACTA2 PROTEIN, HUMAN; ACTIN; ARECOLINE; HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ARECA; BIOSYNTHESIS; CELL TRANSDIFFERENTIATION; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENETICS; HUMAN; MASTICATION; METABOLISM; MOUTH DISEASE; MOUTH MUCOSA; MYOFIBROBLAST; PATHOLOGY; PRIMARY CELL CULTURE; PROMOTER REGION;

ACTINS; ARECA; ARECOLINE; CELL TRANSDIFFERENTIATION; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HOMEODOMAIN PROTEINS; HUMANS; MASTICATION; MOUTH MUCOSA; MYOFIBROBLASTS; ORAL SUBMUCOUS FIBROSIS; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS;

EID: 84897966251     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12219     Document Type: Article

References (36)

1. Tilakaratne WM, Klinikowski MF, Saku T, et al. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol. 2006; 42: 561-8.
2. Yang YHLH, Tung S, Shieh TY. Epidemiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan. J Oral Pathol Med. 2001; 30: 213-9.
3. Utsunomiya H, Tilakaratne WM, Oshiro K, et al. Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. J Oral Pathol Med. 2005; 34: 498-507.
4. Moutasim KA, Jenei V, Sapienza K, et al. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol. 2011; 223: 366-77.
5. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J Biomech. 2010; 43: 146-55.
6. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170: 1807-16.
7. Yang SFHY, Tsai CH, Chou MY, et al. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis. Oral Oncol. 2003; 39: 367-72.
8. Tsai CH, Yang SF, Chen YJ, et al. The upregulation of insulin-like growth factor-1 in oral submucous fibrosis. Oral Oncol. 2005; 41: 940-6.
9. Ni WFTC, Yang SF, Chang YC. Elevated expression of NF-kB in oral submucous fibrosis-evidence for NF-kB induction by safrole in human buccal mucosal fibroblasts. Oral Oncol. 2007; 43: 557-62.
10. Chang YC, Tsai CH, Tai KW, et al. Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral Oncol. 2002; 38: 425-30.
11. Gheldof A, Hulpiau P, van Roy F, et al. Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci. 2012; 69: 2527-41.
12. Watanabe Y, Kawakami K, Hirayama Y, et al. Transcription factors positively and negatively regulating the Na, K-ATPase alpha 1 subunit gene. J Biochem. 1993; 114: 849-55.
13. Putta S, Lanting L, Sun G, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012; 23: 458-69.
14. Aigner K, Descovich L, Mikula M, et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 2007; 581: 1617-24.
15. Yang SF, Tsai CH, Chang YC. The upregulation of heat shock protein 47 expression in human buccal fibroblasts stimulated with arecoline. J Oral Pathol Med. 2008; 37: 206-10.
16. Nayak MT, Singh A, Desai RS, et al. Immunohistochemical analysis of vimentin in oral submucous fibrosis. J Cancer Epidemiol. 2013; 2013: 549041.
17. Blank RS, McQuinn TC, Yin KC, et al. Elements of the smooth muscle alpha-actin promoter required in cis for transcriptional activation in smooth muscle. Evidence for cell type-specific regulation. J Biol Chem. 1992; 267: 984-9.
18. Lee SS, Yang SF, Tsai CH, et al. Upregulation of heme oxygenase-1 expression in areca-quid-chewing-associated oral squamous cell carcinoma. J Formos Med Assoc. 2008; 107: 355-63.
19. Lee SS, Yang SF, Ho YC, et al. The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol. 2008; 44: 180-6.
20. Chang YC, Yang SF, Tai KW, et al. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol. 2002; 38: 195-200.
21. Jung YS, Liu XW, Chirco R, et al. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS ONE. 2012; 7: e38773.
22. Yu CC, Tsai CH, Hsu HI, et al. Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral submucous fibrosis. PLoS ONE. 2013; 8: e55122.
23. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol. 2011; 301: G950-5.
24. Nishimura G, Manabe I, Tsushima K, et al. DeltaEF1 mediates TGF-beta signaling in vascular smooth muscle cell differentiation. Dev Cell. 2006; 11: 93-104.
25. Khan I, Kumar N, Pant I, et al. Activation of TGF-beta pathway by areca nut constituents: a possible cause of oral submucous fibrosis. PLoS ONE. 2012; 7: e51806.
26. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19: 156-72.
27. Chang MC, Lin LD, Wu HL, et al. Areca nut-induced buccal mucosa fibroblast contraction and its signaling: a potential role in oral submucous fibrosis-a precancer condition. Carcinogenesis. 2013; 34: 1096-104.
28. Lorenzatti G, Huang W, Pal A, et al. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. J Cell Sci. 2011; 124: 1752-8.
29. Yasuda Y, Shimizu M, Sakai H, et al. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem Biol Interact. 2009; 182: 159-64.
30. Choi JE, Lee SS, Sunde DA, et al. Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury. Am J Respir Crit Care Med. 2009; 179: 212-9.
31. Avon SL. Oral mucosal lesions associated with use of quid. J Can Dent Assoc. 2004; 70: 244-8.
32. Angadi PV, Rao S. Management of oral submucous fibrosis: an overview. Oral Maxillofac Surg. 2010; 14: 133-42.
33. Jiang X, Hu J. Drug treatment of oral submucous fibrosis: a review of the literature. J Oral Maxillofac Surg. 2009; 67: 1510-5.
34. Hu FW, Tsai LL, Yu CH, et al. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res. 2012; 56: 1247-58.
35. Liu LC, Tsao TC, Hsu SR, et al. EGCG inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells. J Agric Food Chem. 2012; 60: 9863-73.
36. Shan Y, Zhang L, Bao Y, et al. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 2013; 24: 1062-9.